The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

1. (Currently amended) A ~~DNA vaccine~~ composition for eliciting an immune response, comprising:

at least one genetic sequence encoding a mutant ADP-ribosyltransferase toxin (mART); and

at least one genetic sequence encoding an antigen.

2. (Currently amended) The ~~DNA vaccine~~ composition of claim 1 wherein said mART is derived from a cholera toxin.

3. (Withdrawn) The DNA vaccine of claim 1 wherein said mART is derived from a pertussis toxin.

4. (Withdrawn) The DNA vaccine of claim 1 wherein said mART is derived from a heat labile toxin of enterotoxigenic *Escherichia coli*.

5. (Currently amended) The ~~DNA vaccine~~ composition of claim 1 wherein said mART includes a mutation selected from the group consisting of R7K, R13H, E29H, H35R, L41F, F50S, S61K, S63K, S63Y, V53D, V97K, Y104K, P106S, H171Y; and combinations thereof.

6. (Currently amended) The ~~DNA vaccine~~ composition of claim 1 further comprising an expression vector, said at least one genetic sequence encoding said mART is associated with said expression vector.

7. (Currently amended) The ~~DNA vaccine~~ composition of claim 6 wherein said at least one genetic sequence encoding said antigen is associated with said expression vector.

8. (Currently amended) The ~~DNA vaccine~~ composition of claim 7 further comprising an internal ribosome entry site positioned between said at least one genetic sequence encoding said mART and said at least one genetic sequence encoding said antigen.

9. (Currently amended) The ~~DNA vaccine~~ composition of claim 6 wherein said expression vector is a eukaryote.

10. (Currently amended) The ~~DNA vaccine~~ composition of claim 9 further comprising at least one eukaryote promoter sequence associated with said expression vector.

11. (Currently amended) The ~~DNA vaccine~~ composition of claim 10 wherein there are at least two eukaryote promoter sequences associated with said expression vector.

12. (Currently amended) The ~~DNA vaccine~~ composition of claim 6 wherein said at least one genetic sequence encoding said antigen is associated with a second expression vector that is separate from said expression vector associated with said at least one genetic sequence encoding a mART.

13. (Currently amended) The ~~DNA vaccine~~ composition of claim 1 wherein said antigen is bacterial.

14. (Currently amended) The ~~DNA vaccine~~ composition of claim 1 wherein said antigen is viral.

15. (Withdrawn) A vaccine composition, comprising:

an antigen; and

at least one genetic sequence encoding a mutant ADP-ribosyltransferase toxin (mART).

16. (Cancel) A vaccine composition, comprising:

a DNA vaccine that expresses an antigen; and

at least one genetic sequence encoding a mutant ADP-ribosyltransferase toxin (mART).

17. (Currently amended) A method of eliciting an immune response in a patient, comprising:

introducing into said patient at least one genetic sequence encoding a mutant ADP-ribosyltransferase toxin (mART) and at least one genetic sequence encoding an antigen;

expressing said mART and said antigen after said introducing step.

18. (Original) The method of claim 1 wherein said step of introducing is accomplished using an expression vector which both said genetic sequence encoding said mART and said genetic sequence encoding said antigen are associated with.

19. (Original) The method of claim 18 wherein said expression vector includes at least two eukaryote promoters.

20. (Original) The method of claim 18 wherein said expression vector includes an internal ribosome entry site positioned between said at least one genetic sequence encoding said mART and said at least one genetic sequence encoding said antigen.